OBJECTIVES: To evaluate the therapeutic efficacy of pioglitazone on psoriasis vulgaris and its comorbidities. MATERIALS AND METHODS:Forty-eight patients with moderate-to-severe psoriasis vulgaris were enrolled in this randomized double blinded placebo-controlled trial. Active treatment included: oral pioglitazone 30 mg daily for 10 weeks. Primary outcome (treatment success) was PASI-75. Secondary outcomes included changes in metabolic syndrome, insulin resistance and cardiovascular risk. RESULTS:Treatment success was achieved in 5/24 (21%) in the pioglitazone group compared to 1/24 (4%) in the placebo group; however, this difference was not significant (p = 0.081). Compared to placebo, no significant difference existed as regards high-sensitive C reactive protein. Metabolic syndrome and insulin resistance were not affected. CONCLUSIONS: This short term (10 weeks duration) study revealed no effect of pioglitazone 30 mg daily neither on the clinical response of moderate-to-severe psoriasis nor on metabolic syndrome and insulin resistance. Cardio-protective role appears to be more related to improvement of psoriasis. LIMITATION: Short duration of treatment and small number of subgroups.
RCT Entities:
OBJECTIVES: To evaluate the therapeutic efficacy of pioglitazone on psoriasis vulgaris and its comorbidities. MATERIALS AND METHODS: Forty-eight patients with moderate-to-severe psoriasis vulgaris were enrolled in this randomized double blinded placebo-controlled trial. Active treatment included: oral pioglitazone 30 mg daily for 10 weeks. Primary outcome (treatment success) was PASI-75. Secondary outcomes included changes in metabolic syndrome, insulin resistance and cardiovascular risk. RESULTS: Treatment success was achieved in 5/24 (21%) in the pioglitazone group compared to 1/24 (4%) in the placebo group; however, this difference was not significant (p = 0.081). Compared to placebo, no significant difference existed as regards high-sensitive C reactive protein. Metabolic syndrome and insulin resistance were not affected. CONCLUSIONS: This short term (10 weeks duration) study revealed no effect of pioglitazone 30 mg daily neither on the clinical response of moderate-to-severe psoriasis nor on metabolic syndrome and insulin resistance. Cardio-protective role appears to be more related to improvement of psoriasis. LIMITATION: Short duration of treatment and small number of subgroups.
Authors: Vladimir V Sobolev; Ekaterina Tchepourina; Irina M Korsunskaya; Natalia A Geppe; Svetlana N Chebysheva; Anna G Soboleva; Alexandre Mezentsev Journal: Int J Mol Sci Date: 2022-08-26 Impact factor: 6.208